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Isolated limb perfusion (ILP) with chemotherapeutic agents
was first introduced by Creech et al. in 1958. Stehlin (1969)
added hyperthermia to this technique and made hyperthermic
isolated limb perfusion (HILP) an interesting method in the
treatment of malignancies of the extremities.
Advantages of ILP are the fact that the tumour is locally
treated with high concentrations of the chemotherapeutic
drug, whereas only low drug concentrations are reached in
the systemic circulation. This is attended by minor or no
systemic side-effects. One case has been described in which
ILP was performed because of a contra-indicative renal
impairment in the treatment with cisplatin (CDDP) (Roseman
et al., 1985). Beneficial effects of ILP are anticipated in the
treatment of poor vascularised tumours and with drugs hav-
ing a high total body clearance. The application of ILP is
limited to drugs which do not need metabolic activation. The
use of an extracorporeal circulation allows hyperthermic
treatment. With CDDP this can be of advantage as hyper-
thermia may enhance its cytoxicity (Fisher & Hahn, 1982;
Hahn, 1979; Herman, 1983; Wallner et al., 1986; Alberts et
al., 1980; Meyn et al., 1980). Enhanced blood flow, due to
vasodilation (Hahn, 1979; Song et al., 1980), enhanced cel-
lular drug uptake (Herman, 1983; Alberts et al., 1980), tissue
extraction (Riviere et al., 1986), DNA cross-linking (Meyn et
al., 1980; Herman et al., 1989) and decreased DNA repair
(Wallner et al., 1986) are postulated to explain the
phenomenon of hyperthermic potentiation. Some selectivity
of treatment might hereby be introduced, because malignant
cells have shown to be more sensitive to heat than normal
cells (Herman, 1983; Herman et al., 1989; Giovanella et al.,
1973; Giovanella et al., 1976; Kase & Hahn, 1975; Cavaliere
et al., 1967). ILP with chemotherapeutic agents can allow
limb saving procedures (Hoekstra et al., 1987; Roseman,
1987).
The technique is improved during the last decade. More
physiological perfusions are performed taking into account
such variables as the patients blood pressure and perfusion
pressure (Fontijne et al., 1985, Van Os et al., 1985; De Vries
et al., 1988; Van Os et al., 1989).
Although several studies on HILP with CDDP were re-
ported in the recent years, little is known about the phar-
macokinetics of the drug in these circumstances.
In this study the pharmacokinetics of total platinum (tPt),
ultrafiltrated platinum (fPt) and CDDP in the perfusate are
presented during HILP for human tumours of the limb. Nine
patients, six with intransit metastases of melanoma, one
metastasised extremity osteosarcoma of the femur and two
with recurrent malignant fibrous histiocytoma (one of the
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soft tissues and one of the femur) were treated with HILP
with CDDP. None of the patients had received systemic
CDDP previously. The patients with recurrent melanoma of
the lower extremity were treated previously with one or two
HILP treatments with melphalan or melphalan and dac-
tinomycin. Patients characteristics are summarised in Table I.
The study was approved by the local medical ethical commit-
tee of the University Hospital Groningen. All patients gave
informed consent.
Prior to the perfusion treatment patients received systemic
i.v. hydration with 2-31 normal saline in 24h to prevent
relative hypovolemia during surgery. During the perfusion
diuresis was monitored to assure diuresis over 50mlh-' in
all patients. All limb perfusions were performed as described
before (Hoekstra et al., 1987). The limb was perfused with
350 ml 5% dextran 40 in glucose 5% (Isodex, Pharmacia AB,
Sweden), 250 ml plasma, 250 ml red blood cells, 30 ml 8.4%
NaHCO3, 0.5 ml 5000 IU ml-' heparin (Thromboliquine,
Organon B.V., Oss, The Netherlands) and 200 to 800 ml
CDDP 0.5 mg ml-', (dependent on dose) (Platinol, Bristol
Myers SAE, Spain) at subcutaneous and muscle temperatures
of 39-40°C with the aid of a pump oxygenator.
CDDP dose, administered as a part of a phase I dose
finding study, was 20mgl1' extremity volume in four pa-
tients, 25 mg 1-' in three patients and 30 mg ml-' in two
patients. Limb toxicity was scored according to Wieberdink
et al. (1982). CDDP was added to the circulating perfusate in
10min. At the end of the CDDP infusion, the first 10ml
perfusate sample was collected (t=Omin) in a heparin
coated glass tube. Additional samples were collected at
10min intervals (t = 10, 20, 30, 40, 50 and 60 min) and
transported on ice immediately. Samples were centrifuged for
10min at 2000g and the cell fraction was removed; in the
supernatant tPt was measured. For determination of fPt
concentrations, 1 ml supernatant samples were ultrafiltrated
(2000g; 60min) with Amicon Centifree micropartition sys-
tems provided with YMT membranes (Amicon, Oosterhout,
The Netherlands). Tissue biopsies were taken for tPt deter-
mination in six patients at the end of the HILP, when the
normal limb circulation was restored. At the end of the
procedure (t =60+ min) the limb was washed out with
1000 ml Isodex (5% dextran 40 in dextrose 5%) and with
250 ml plasma and 250 ml red blood cells respectively.
Thereafter, the systemic circulation was restored.
Leakage, from the perfused limb to the patients circulation
was determined during the perfusion with '3'I-albumin and
9'Tc-albumin. A small dose (about 10piCi) of '31I-albumin is
injected in the body circulation and exactly ten times the
small dose is injected in the external circulation. The 99Tc-
albumin is injected in the body circulation only; its activity is
recorded for the detection of dilution by infusion and shift of
the detector sensitivity by displacement of the detector. A
scintillation counter, placed over the heart, detects the
amount of "mTc- and "3'I-labelled albumin in the body cir-
culation. In the two patients with popliteal perfusion leakage
was not monitored with isotopes. Leakage was also deter-
mined by measuring patients tPt plasma concentration at the
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Table I Patient characteristics
Age Limb volume CDDP dose CDDP dose
Patient (years) Tumour (1) (mgi') (mg) Location ofperfusion
1 21 Osteosarcoma 13.0 20 260 Iliacal
2 66 Melanoma 7.5 20 150 Popliteal
3 56 Melanoma 8.8 20 180 Iliacal
4 66 Melanoma 8.0 20 160 Femoral
5 70 Fibrous histio- 11.0 25 275 Iliacal
cytoma (bone)
6 56 Melanoma 15.6 25 390 Femoral
7 72 Melanoma 12.0 25 300 Iliacal
8 58 Fibrous histio- 3.3 30 100 Popliteal
cytoma (soft
tissue)
9 59 Melanoma 13.0 30 400 Iliacal
end of each perfusion procedure and in two patients during
the seven days following the perfusion as well.
Concentrations tPt and fPt in the perfusate were deter-
mined by flameless atomic absorption spectrophotometry
(FAAS). Absorption was measured at 265.9 nm with a spec-
tral band-width of 0.5 nm and deuterium background signal
correction. Perfusate tPt samples were diluted with three
volumes 23-laurylether 0.3% w/v (Brij 35 Solution, Sigma
Chemicals Company, St Louis, USA) and were analysed
without further pretreatment. The method has a detection
limit of 0.1 mg Pt I` and a standard deviation of 7.7% at a
concentration of 12 mg tPt 1-'. Tissue tPt concentrations
were determined with FAAS using standard addition method
with Pt chloride. Tissue was weighted and dissolved in 65%
nitric acid under heating to 80-90°C and diluted to 2.5 ml
with demineralised water. Each sample was measured in
duplicate. Plasma tPt concentrations were measured by
FAAS after diluting the 100 tl sample with 300 1l Brij 35.
CDDP concentrations were measured by HPLC, equipped
with an anion exchange Nucleosil 5SB 5 ytm column (Bouma
& Uges, 1980), and UV detection (230 nm). Eluens consisted
of methanol:sodium acetate 0.1 M (65:35 v/v%) with
sufficient acetic acid to pH = 5.0. A standard solution of
20.0 mg CDDP in 1.0 I NaCl 0.9% was used. Ultrafiltrate
perfusate samples of 20,ul were directly injected in the HPLC
column. This method has a detection limit of 0.3 mg I` and
an intra assay standard deviation of 1.9% at a concentration
of 20.0 mg CDDP l1. The calibration curve (0-20mg
CDDP l-) was found linear (r = 0.999); the inter assay stan-
dard deviation was 2.9%. Each sample was measured in
duplicate.
For tPt, fPt and CDDP perfusate elimination kinetics, data
were subjected to logarithmic regression analysis (concen-
tration = A.e-kt). The areas under the concentration vs time
curves (AUC) were calculated using the model independent
trapezoidal rule (Rowland & Tozer, 1980) and covers the
perfusion period (t = 0-60 min). Data were analysed by the
two sided Student's t-test. Only P-values <0.05 were con-
sidered significant.
The local grade of toxicity is summarised in Table II. The
grade of toxicity was not correlated to the dosage (in mg 1-'
limb volume) but to the total amount of delivered CDDP,
AUC of tPt and Cmax. Limb toxicity consisted of a mod-
erate to severe limb oedema and a motor-sensory neuro-
pathy, documented with electro-myography in five patients.
Electromyography showed denervation potentials with distur-
bances in the motory and sensory conduction velocities of the
peroneal and sural nerve of the affected limb.
In all patients tPt concentrations were determined, whereas
fPt and CDDP concentrations were determined only in
patients 7-9. The data from patients 8 and 9 should be
considered separately, as patient 8 had a much smaller limb
volume (due to popliteal perfusion) compared to patient 9.
After 60 min perfusion a decrease of 54.3 ± 12.4% (n = 9),
79.9 ± 14.7% (n = 3) and 79.2 ± 4.2% (n = 3) (mean ± s.d.)
of concentrations of tPt, fPt and CDDP in the perfusate was
observed, indicating considerable extraction. The perfusate
concentrations versus time show good linear correlation
(r = 0.95 ± 0.07) when represented semi-logarithmically and
therefore first order kinetics was assumed (C = A.e-kt). Phar-
macokinetic parameters of all patients are summarised in
Table II. The mean ti for tPt (51.2 ± 13.0 min) was found to
be higher (P<0.005) than for fPt and CDDP (28.3 ± 11.7
min and 27.3 ± 3.2min, respectively), whereas the latter two
are not significantly different. The AUCs, representing tissue
drug exposure, are also depicted in Table II. Systemic plasma
concentrations of tPt, determined at the end of the perfusion,
before restoration of the normal circulation were found to be
relatively low (<0.5-21.4jiM). The mean leakage of the
limb to the patients circulation as determined with radioac-
tive albumin was 3.3% (range 0-9.5%). During 7 days after
the perfusion, systemic plasma tPt concentrations ofpatient 8
(popliteal perfusion) were <0.5jM and of patient 7 (iliacal
perfusion), it dropped from 12.4 to 3.5-4.41LM.
Figure 1 shows the mean fraction fPt:tPt during the
perfusion. It is decreased to 40 + 8% (n = 3) after 60min
perfusion (P<0.01). The mean fraction fPt was 71 ± 22%
during the entire perfusion.
Concentrations in tissue biopsies taken from the tumour
and surrounding tissues are summarised in Table III. A wide
variation in concentrations within patients and tissues is
observed, but especially high tPt concentrations are found in
the skin.
Using the normal i.v. route of CDDP administration
therapeutic tPt concentrations of 0.5-5 mg1' (2.5-25jiM)
are reached during the first 48 h after bolus dose or during 5
days of continuous infusion (Gullo et al., 1980; Gormley et
al., 1979; Vermorken et al., 1982; Bues-Charbit, et al., 1987).
This study shows that much higher concentrations can be
reached with HILP. During the whole perfusion period high
tPt concentrations can be reached which would be unaccep-
tably toxic at systemic use. Despite the same dosage applied
per liter limb volume, we found much smaller perfusate drug
concentrations in patient 8 compared to patient 9. This is
attributable to the small limb volume in patient 8 with a
popliteal perfusion. In these circumstances there is a greater
relative dilution of CDDP in the perfusate. One should take
this into account when extremely large or small limbs are
perfused. This finding underscores the relevance of the assess-
ment of the actual exchangeable blood volume as described
by Lejeune et al. (Lejeune & Ghanem, 1987) and thus cal-
culating the drug dose necessary to get the desired drug
concentrations in isolated perfusion. Furthermore, this fact
makes the correlation of toxicity and pharmacokinetic para-
meters in our study difficult. In the past the dosage of
chemotherapeutics used in ILP was based on body weight.
Since the studies of Wieberdink and Fontijne, today calcula-
tion of dosage is based on the volume of the perfused limb.
However, for pharmacokinetic purposes dose calculation ac-
cording to Lejeune should be considered preferable as in our
study CDDP toxicity was correlated to the total dose de-
livered instead of to the dose per liter limb volume. From our
toxicity data we conclude that the total dose of CDDP
should not exceed 275 mg. This is in accordance to the900 H.-J. GUCHELAAR et al.
Table II Pharmacokinetic parameters oftPtin theperfusate and offPtand CDDPin ultrafiltrated
perfusate during 60 min HILP with 20, 25 or 30mg CDDP I-1 extremity, assuming first order
kinetics, leakage data and toxicity
Systemic tPt Maximalleakage
t4 Cmax C,-60 AUC concentration radiolabelled Local toxicity
Patient (min) (pM) ("lM) (pM.min) (JLM) albumin (%) grade
Total Pt
1 65 249 174 11035 13.3 4.2 III
2 41 287 113 9480 3.6 nd III
3 42 318 123 12095 6.1 0.0 III
4 54 286 128 12020 <0.5 3.0 III
5 53 349 164 13485 6.6 2.1 III
6 67 507 272 25065 <0.5 0.0 IV
7 37 410 145 15255 21.4 9.5 IV
8 37 386 107 10195 <0.5 nd II
9 69 594 318 26190 1.0 4.2 IV
LTltrafilterable Pt
7 18 525 10518
8 26 338 7085
9 41 570 21870
Ultrafilterable CDDP
7 25 246 7121
8 26 260 5530
9 31 309 10195
Toxicity (according toWieberdink) grade I: no subjective orobjectiveevidence ofreaction, grade II:
slight erythema and/or oedema, grade III: considerable erythema and/or oedema with some
blistering; slightly disturbed motility permissible, grade IV: extensive epidermolysis and/or obvious
damage to the deep tissues, causing definite functional disturbances, threatening or manifest
compartmental syndromes, grade V: reaction which may necessitate amputation. nd = not
determined, in patients with popliteal perfusion.
40-
Time (min)
1 Mean fraction fPt:tPt in the perfusate during 60 min
findings of Coit et al. (1991) and Di Fillipo et al. (1989) who
defined a maximum tolerated dose of 150 mg CDDP m-2 and
3.2 mg CDDP kg-' body weight, respectively.
Our albumin leakage data and systemic tPt concentrations
show that HILP was performed with relatively low leakage
to the patients systemic circulation. However, higher than
neglectable systemic tPt concentrations were found in some
patients. Because of the high doses applied at HILP, hydra-
tion of the patients remains necessary to avoid systemic
toxicity. No systemic side-effects, but temporary or definitive
local motoric and sensoric symptoms in the perfused limb
were observed.
Others found leakage of 2.5% leading to systemic tPt
concentrations of 2.6-3.1tM Pt during 60 min perfusion and
3.6-5.1I1M Pt during 5 postoperative days (Di Filippo et al.,
1989). Pommier et al. (1988) found a mean systemic tPt level
of 2.5ftM Pt at 5 min after the start of the perfusion and
3.9pM Pt after 60 min perfusion in patients with malignant
melanoma. They monitored leakage only by measuring sys-
temic tPt concentrations.
The mean ti for fPt and CDDP were found to be smaller
than for tPt. This is probably due to the fact that the free Pt
species leave the vascular compartment and cross plasma
membranes more readily compared to protein-bound species.
A very high fraction fPt was found. At normal i.v. adminis-
Table III Tissue drug concentrations (nmol tPt g-' tissue) in tumour and
adjacent tissue after 60 min HILP
Concentration tPt in per
Patient Skin Fat Muscle Tumour fusate at t = 60min CuM)
1 97.4 nd 20.5 87.1 174
2 66.6 nd 23.6 116.4 113
3 113.8 nd 1.0 32.3 123
4 nd nd nd nd 128
5 179.4 133.3 174.3 21.0 164
109.2a 13.3a 22.6a 15.9a
6 nd nd nd nd 272
7 116.4 nd 21.0 74.3 145
8 106.1 nd 78.4 98.9 107
57.9b
9 nd nd nd nd 318
a14 days post perfusion. b8 days post perfusion. nd: not determined.
Figure
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tration of CDDP the fraction fPt is about 0.05-0.10 (Ver-
morken et al., 1982; Bues-Charbit et al., 1987; Dominici et
al., 1989; Forastiere et al., 1988). The four- to twenty-fold
increase of the free fraction in this study is most probably
attributable to the low protein content of the perfusate. This
is an advantage as free drug concentrations are more closely
related to drug activity and thus probably anti-tumour effect.
At the start of the perfusion all Pt was unbound whereas a
gradual increase of protein binding was observed during
perfusion time. This may be explained by the fact that the
parent compound (CDDP) itself does not bind to protein
whereas its hydrolytic products do (LeRoy et al., 1979).
These products are formed in aqueous solutions with a half-
life of 6-8 h at 25°C and probably even faster at tempera-
tures applied at HILP (LeRoy et al., 1979).
In literature data about tissue Pt exposure at HILP are
scarce. Di Filippo et al. (1989) found about the same AUCs
for tPt after approximately the same dosage CDDP at 60 min
HILP as reported here, however, data on intact CDDP and
elimination rate constants are absent in their study.
Although perfusate concentrations varied minimally
among individuals, tissue concentrations in normal as well as
malignant tissue were shown to vary in a wide range. Di
Fillippo et al. (1989) have found similar results. Bielack et al.
(1989), recently found a large intra-tumour variation of Pt
distribution in patients with osteosarcoma treated with int-
raarterial or i.v. infusion of CDDP. Some variation might be
explained by differences in tissue water content, as samples
were not dried before tPt determination. The high Pt accu-
mulation in skin supports the application of HILP in
melanoma. It might be more realistic to express tissue con-
centrations per g protein or DNA content instead of per
tissue weight or to determine the amount of Pt-DNA adducts
formed (Terheggen et al., 1988).
In conclusion, with HILP substantial drug extraction
occurs, with relatively low leakage to the patients systemic
circulation. With the described method it is possible to reach
a considerable higher fraction of free drug compared to
normal i.v. CDDP administration without systemic toxicity.
ILP offers the opportunity to modify the perfusate composi-
tion such that it favourably influences CDDP kinetics.
J. Ymker and A. Groefsema of the Department of Pharmacy of the
University Hospital of Groningen are gratefully acknowledged for
measurements of platinum and cisplatin concentrations.
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